Indaptus Therapeutics (INDP) announces it has named Robert Martell, M.D., Ph.D. to its Board of Directors. Having been in the pharmaceutical industry for more than 20 years, Dr. Martell currently serves as Head of Research and Development, as well as previously serving on the Board of Directors for more than six years at Curis (CRIS).
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INDP:
- Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors
- Indaptus activates Morristown Medical Center as trial site for INDP-D101
- Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
